Latest on Anabolic Agents for Osteoporosis Treatment

被引：2

作者：

di Filippo, Luigi ^{[1
,2
]}

Rosen, Clifford J. ^{[3
]}

机构：

[1] Univ Vita Salute San Raffaele, Inst Endocrine & Metab Sci, Milan, Italy

[2] IRCCS Osped San Raffaele, Milan, Italy

[3] Main Ehlth Inst Res, Ctr Clin & Translat Res, Scarborough, ME 04074 USA

来源：

ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA | 2024年 / 53卷 / 04期

关键词：

Osteoporosis; Anabolics; Teriparatide; Abaloparatide; Romosozumab; Blosozumab; Fragility fractures; Glucocorticoids; PARATHYROID-HORMONE; 1-34; BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; DOUBLE-BLIND; ABALOPARATIDE; TERIPARATIDE; ROMOSOZUMAB; FRACTURE; RISK; PLACEBO;

D O I：

10.1016/j.ecl.2024.08.003

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The efficacies of anabolic compounds in preventing fragility fractures and increasing BMD were progressively and widely demonstrated in the last decades. Latest updated clinical data (Table 1) in this setting have markedly downgrading their potential serious side effects including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further future data are warranted about their potential efficacy in patients with GIO and, interestingly, their use is currently investigated also in fracture healings setting.

引用

页码：513 / 523

页数：11

共 50 条

[31] Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis
Lyritis, George P.
Georgoulas, Thomas
Zafeiris, Christos P.
WOMEN'S HEALTH AND DISEASE, 2010, 1205 : 277 - 283
[32] Indications to teriparatide treatment in patients with osteoporosis
Rizzoli, Rene
Kraenzlin, Marius
Krieg, Marc-Antoine
Mellinghoff, Hans-Ulrich
Lamy, Olivier
Lippuner, Kurt
SWISS MEDICAL WEEKLY, 2011, 141
[33] Romosozumab for the treatment of osteoporosis - a systematic review
Maekinen, V. -n.
Solling, A. S.
Mcclung, M.
Langdahl, B. L.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2025, 48 (03) : 547 - 572
[34] Treatment needs and current options for postmenopausal osteoporosis
Gennari, Luigi
Rotatori, Stefano
Bianciardi, Simone
Nuti, Ranuccio
Merlotti, Daniela
EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1141 - 1152
[35] Treatment options for glucocorticoid-induced osteoporosis
Chiodini, Iacopo
Merlotti, Daniela
Falchetti, Alberto
Gennari, Luigi
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) : 721 - 732
[36] Combination and sequential treatment in women with postmenopausal osteoporosis
Anastasilakis, Athanasios D.
Polyzos, Stergios A.
Yavropoulou, Maria P.
Makras, Polyzois
EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (04) : 477 - 490
[37] High fracture risk patients with glucocorticoid-induced osteoporosis should get an anabolic treatment first
Lespessailles, E.
Chapurlat, R.
OSTEOPOROSIS INTERNATIONAL, 2020, 31 (10) : 1829 - 1834
[38] Romosozumab for the treatment of osteoporosis
Bandeira, Leonardo
Lewiecki, E. Michael
Bilezikian, John P.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (02) : 255 - 263
[39] Combination of anabolic and antiresorptive agents for the treatment of osteoporosis
Garcés, C
García, LE
MATURITAS, 2006, 54 (01) : 47 - 54
[40] The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis
Yavropoulou, Maria P.
Xygonakis, Christos
Lolou, Maria
Karadimou, Fotini
Yovos, John G.
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2014, 13 (04): : 476 - 487

← 1 2 3 4 5 →